Atropine

Atropine is a competitive muscarinic antagonist and is also used as a positive chronotrope.

| Indications | Presentation |
|--|---|
| Organophosphate & carbamate poisoning | - 0.6 mg/mL ampoule OR 1.2 mg/mL ampoule |
| Poisoning by agents that impair AV conduction: | - Compatible fluids: Glucose 5%, Compound Sodium Lactate (CSL), Plasma-Lyte 148, Sodium Chloride 0.9%, |
| -Calcium Channel Blockers (CCB) | Glucose 4% and NaCl 0.18% |
| -Beta blockers | |
| -Cardiac glycosides | Dose and Administration (Cardiac monitoring is mandatory during administration) |
| Initial Rx of clonidine-induced hypotension | Organophosphate, nerve agent (acetylcholinesterase inhibitor) & carbamate poisoning |
| with associated bradycardia | Administer to all patients with muscarinic symptoms. |
| | - 1.2 mg (0.05 mg/kg children, up to 1.2 mg) IV bolus and double dose every 5 minutes |
| Contraindications | - Continue IV boluses until adequate atropinisation is achieved: |
| Anticholinergic toxicity | ADEQUATE ATROPINISATION: HR > 80 bpm, systolic BP > 90 mmHg, chest clinically clear |
| Closed angle glaucoma (relative CI) | - In cases of OP poisoning, reported cumulative doses of atropine required to achieve adequate atropinisation |
| | varies widely (from 10 to 100 mg). |
| Adverse effects: | - Once adequate atropinisation is achieved, commence atropine infusion: 10-20% of the total dose required to |
| Anticholinergic excess: delirium, tachycardia, | achieve adequate atropinisation per hour. Rare to require > 3-5mg/hour atropine per hour. |
| mydriasis, urinary retention | - Titrate to effect and monitor for possible anticholinergic toxicity (confusion, pyrexia, absent bowel sounds) |
| | Bradycardia with CVS compromise (hypotension) caused by drug-induced AV conduction blockade |
| | - 0.6 mg (0.02 mg/kg children, up to 0.6 mg) IV bolus and repeat dose 15 minutely up to 1.8 mg as required |
| | |
| | Pregnancy: Safe to use in pregnancy |

AUSTIN CLINICAL TOXICOLOGY SERVICE GUIDELINE